- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01484912
Phase II Study of STA-2 in Patients With Chronic Stable Angina
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of STA-2 in Patients With Chronic Stable Angina
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study was to evaluate the efficacy of STA-2 in the management of chronic stable angina. The secondary objectives of this study were to evaluate the safety and pharmacological activities of STA-2 in the management of chronic stable angina. This was a multi-center, double-blind, randomized, parallel-group, placebo-controlled study of STA-2 in the management of chronic stable angina. The study period for each patient was approximately 7 weeks, during which the patient undergone one-week screening and washout period, followed by 6 weeks of treatment. Each patient was required to make a total of 5 visits. Primary Efficacy Endpoint: Change in total exercise time.
After washout, patients who met the inclusion and exclusion criteria were randomly assigned either to the treatment or control group. The respective regimens were:
Treatment group:
STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules ter in die (t.i.d.=three times daily) for 6 weeks, to be administered in a non-fasting state.
Control group:
Placebo 250 mg capsule, 2 capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tainan, Taiwan
- Chi Mei Medical Center
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female aged > 20;
- Patients who had effort-induced angina which was relieved by rest or nitroglycerin, or who had catheterization-documented coronary artery disease or previous myocardial infarction ≥ 3 months before screening;
- Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) at screening (Day -7);
- Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) on the day of enrollment (Day 0). ETT performance between Day -7 and Day 0 were required not differ by >20% in total exercise time;
Female patient who was in the post-menopausal stage or of childbearing potential who:
- used adequate contraception since last menstruation and no plan for conception during the study;
- was non-lactating;
- had negative pregnancy test (urine) within 14 days prior to the study;
- Able to provide written informed consent.
Exclusion criteria:
- Patients with pre-excitation, conduction abnormalities, pacemaker rhythm, unstable angina or myocardial infarction within the preceding 3 months;
- Patients with heart failure (New York Heart Association class III or IV), uncorrected valvular or congenital heart disease, patients who needed digoxin, isosorbide mononitrate, nitroglycerin sustained release preparation, theophylline, class I antiarrhythmic agents, digitalis, or monoamine oxidase inhibitors, as judged by the investigator;
- Patients with any EKG abnormalities preventing the interpretation of ischemia (complete left bundle branch block);
- Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators;
- Patients with hepatic failure (defined as aspartate transaminase (AST) and/or alanine transaminase (ALT) > 3X the upper limit of normal values), and/or renal failure (defined as serum creatinine > 3 mg/dL);
- Patients with severe gastrointestinal illness as judged by the investigator;
- Patient with any conditions that interfered the performance of exercise tolerance test as judged by investigator (e.g., knee/ankle arthropathy, Parkinsonism, stroke).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STA-2
STA-2 250 mg capsule, each containing 100 mg green tea polyphenols. Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state. |
After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was: STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state. |
Placebo Comparator: Placebo
Placebo capsule, containing non-active ingredients. Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state. |
After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was: Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Exercise Time
Time Frame: baseline (visit 2) and week 6 (visit 5)
|
Total exercise time was defined as the maximal duration of exercise which was performed by the patient in the setting of exercise tolerance tests (ETT).
A 12-lead electrocardiogram (EKG) was used to continuously monitor vital signs.
Patients were asked to complete 9-12 minutes of exercise or to exercise until 85% of the maximum predicted heart rate was reached.
All exercise tolerance tests used a standard Bruce multistage exercise test protocol.
|
baseline (visit 2) and week 6 (visit 5)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Time to 1mm ST-segment Depression During Exercise Tolerance Testing (ETT).
Time Frame: baseline (visit 2) through week 6 (visit 5)
|
Time to 1 millimeter (mm) ST-segment depression was recorded from Electrocardiogram (EKG) during exercise tolerance testing (ETT).
The 1mm ST-segment depression may be seen in typical angina patient.
It means the ST segment of EKG wave drops at least 1 mm compared to the beginning of EKG measurement.
|
baseline (visit 2) through week 6 (visit 5)
|
Change in Consumption of Short-acting Nitrates
Time Frame: from baseline (visit 2) through week 6 (visit 5)
|
The consumption of short-acting nitrates from baseline (V2, Day 0) to all visits [V3 (Day 14±2), V4 (Day 28±2), V5 (Day 42±2)]according to patient's diary.
|
from baseline (visit 2) through week 6 (visit 5)
|
Change in Rate-pressure Product
Time Frame: baseline (visit 2) to week 6 (visit 5)
|
Rate-pressure product was defined as the product of heart rate and systolic blood pressure, which was measured both at rest and at peak of exercise.
|
baseline (visit 2) to week 6 (visit 5)
|
Change in Pharmacological Parameters
Time Frame: baseline (visit 2) to week 6 (visit 5)
|
The level of oxidative stress parameters (isoprostane, homocysteine), homeostasis parameters (PAI-I activity), inflammatory markers (fibrinogen, hsCRP, soluble CD40 ligand) and cardiac enzymes (CPK-MB and LDH), were measured to assess the pharmacological activity of STA-2.
|
baseline (visit 2) to week 6 (visit 5)
|
Consumption of Short-acting Nitrates
Time Frame: The consumption of short-acting nitrates from baseline (V2, Day 0) to all visits [V3 (Day 14±2), V4 (Day 28±2), V5 (Day 42±2)]according to patient's diary.
|
The consumption of short-acting nitrates from baseline (V2, Day 0) to all visits [V3 (Day 14±2), V4 (Day 28±2), V5 (Day 42±2)]according to patient's diary.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Unno T, Tago M, Suzuki Y, Nozawa A, Sagesaka YM, Kakuda T, Egawa K, Kondo K. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Br J Nutr. 2005 Apr;93(4):543-7. doi: 10.1079/bjn20041379.
- Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. 2003 Jun 23;163(12):1448-53. doi: 10.1001/archinte.163.12.1448.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCCD05014A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Stable Angina
-
Fundação Educacional Serra dos ÓrgãosCompletedChronic Stable Angina PectorisBrazil
-
Benha UniversityCompletedChronic Stable Angina
-
Tasly Pharmaceuticals, Inc.RecruitingChronic Stable Angina PectorisUnited States
-
Neovasc Inc.Shockwave Medical, Inc.Active, not recruitingAngina Pectoris | Chronic Stable Angina | Angina Pectoris, StableNetherlands, Spain, United Kingdom, Germany, Italy, Switzerland, Belgium, France, Austria
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityUnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...Unknown
-
Clinical Centre of SerbiaFondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, ItalyCompletedRefractory Angina | Chronic Stable AnginaSerbia
-
Roxane LaboratoriesCompletedHypertension | Vasospastic Angina | Chronic Stable AnginaUnited States
Clinical Trials on STA-2
-
Sinphar Pharmaceutical Co., LtdCompleted
-
Patrick MurphyResMed; ResMed Foundation; Guy's & St Thomas' Charity; Respironics InternationalCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Synta Pharmaceuticals Corp.CompletedNon Small Cell Lung CancerUnited States
-
Synta Pharmaceuticals Corp.CompletedLymphoma | Leukemia | Hematological Malignancies | Metastatic or Unresectable Solid TumorsUnited States
-
David M. Jackman, MDMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...CompletedSmall Cell Lung CancerUnited States
-
University of Alabama at BirminghamActive, not recruitingGingival Recession | Lack of Keratinized GingivaUnited States
-
University of Alabama at BirminghamActive, not recruitingGingival RecessionUnited States
-
Memorial Sloan Kettering Cancer CenterSynta Pharmaceuticals Corp.Completed
-
Synta Pharmaceuticals Corp.CompletedSolid TumorsUnited States